Reducing length of hospital stay with colchicine

Abstract

Introduction: Colchicine is an ancient agent with well-known anti-inflammatory effects and commonly used in treatment of hyperinflammatory conditions. It has been argued that colchicine could be an appropriate treatment option in COVID-19 to control hyperinflammatory response. Here in this study, we aimed to investigate the impact of colchicine on outcomes of COVID-19 in our inpatient cohort.
 Methodology: In this retrospective cohort study, hospitalized COVID-19 patients were investigated. Demographics, comorbidities, COVID-19 symptoms, laboratory findings on admission and discharge, baseline and seventh day oxygenation status, rates of mortality, intensive care unit admission, administration of other anti-inflammatory treatments and length of hospital stay were compared between patients who received standard of care medications and who received colchicine additionally.
 Results: Three hundred and thirty-six patients were included in the study (171 standard of care, 165 standard of care plus colchicine). The median length of hospital stay in colchicine group was significantly shorter. Rates of admission to intensive care unit, anti-inflammatory treatment administration and mortality did not differentiate between standard of care and colchicine groups. However, reduced rates of mortality and ICU admission were observed in patients who received colchicine with a dose of 1 mg/day when compared to patients who received 0.5 mg/day.
 Conclusions: Our study demonstrated that COVID-19 patients who received colchicine in addition to standard of care had shorter hospital stay. Our results further support the use of colchicine in treatment of COVID-19, particularly with a dose of 1 mg/day.

Temporal changes in biomarkers of neutrophil extracellular traps and NET‐promoting autoantibodies following adenovirus‐vectored, mRNA, and recombinant protein COVID‐19 vaccination

“…In considering potential mitigating treatments, glucocorticoids 43–46 may contribute to the reduction of autoantibodies, and in turn decrease NETosis and enhance recovery from NETosis‐related conditions. Colchicine and DNase I are both recognized as therapies that target NETs, 47–51 but more research is warranted to ascertain their effectiveness in managing post‐COVID‐19 vaccination side effects. These findings offer crucial insights for refining risk assessments and development of future vaccines.…”

Effect of increasing doses of colchicine on the treatment of 333 COVID‐19 inpatients

“…Karakaş et al noted, even when comparing low doses of colchicine of 1 with 0.5 mg per day, beneficial effect of higher colchicine dosages. 33 …”

“…32 Karakaş et al noted, even when comparing low doses of colchicine of 1 with 0.5 mg per day, beneficial effect of higher colchicine dosages. 33 T A B L E 7 Pooled data, separated by initial loading dose. Increasing doses of colchicine positively enhances the treatment of COVID-19, but the doses administered so far are far from effective.…”

FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities

“…Retrospective studies of colchicine in patients with COVID-19 have already shown good results, with no major adverse effects in non-hospitalized [ 33 ] and hospitalized patients in terms of reduction in hospitalization and recovery time [ 34 – 36 ], progression to intubation [ 37 ], and mortality [ 34 , 35 , 37 – 39 ].…”